NCI Genomic Characterization Centers

The National Cancer Institute established this Master IDIQ for genomic characterization services on August 31, 2019, with a shared ceiling of $49.8 million, but ordering closed on August 30, 2024. This vehicle is no longer open for new task orders.

The vehicle procures high-resolution, genome-wide characterization services of cancer-related genomic alterations across three technical pools: DNA sequencing (whole genome, whole exome, and targeted), RNA sequencing, and protein characterization. Work supports the Center for Cancer Genomics research programs and deposits resulting data into the Genomic Data Commons. Contractors must demonstrate validated, high-throughput methods and process a minimum of 100 samples monthly.

Thirteen task orders have been awarded. The Broad Institute, Inc. dominates the vehicle with three orders totaling $26.1 million combined potential value—roughly 76% of all obligated funds. University of North Carolina at Chapel Hill holds two orders valued at $5.3 million combined; Azenta US Inc. holds two orders at $2.3 million combined. New York Genome Center, Inc. and Genewiz, LLC round out the prime base with one order each. All orders are unrestricted, non-set-aside awards. The National Cancer Institute is the sole customer across all 13 task orders.

Obligated activity has concentrated in the first two years: seven orders in 2019, three in 2020, two in 2021, and one in 2024. Combined task-order potential value totals $34.2 million, with $34.1 million obligated (100% of potential value). Task orders are firm fixed price with durations ranging from one year (early proof-of-concept orders at $2,000 to $190,664) to five years (production orders at $1.8 million to $19.6 million). The largest single award, a DNA characterization services order to The Broad Institute at $19.6 million, represents the core production work supporting multiple NCI programs including CRS/EOMI, CPTAC, and DCEG.

Since ordering has closed and the vehicle has been fully obligated, this is not an active pursuit vehicle.

The Center for Cancer Genomics (CCG) provides genomic characterization services through several Genomic Characterization Centers (GCC) to NCI programs and deposits the resulting data in the Genomic Data Commons, a large-scale database of cancer genomic data for public use. The objective of this project is to acquire high-resolution, systematic, comprehensive (genome-wide) characterization services of cancer-related genomic alterations. The contractor(s) shall function as a fundamental resource and play a key role in the CCG research programs. Key goals shall include ensuring that standards are developed, implemented, continually improved, and maintained to support the entire genomic characterization pipeline. Study variables shall be minimized with rigorous Quality Assurance/Quality Control of all parts of the operation.